U.S. launch of Novo's new insulin faces long delay

U.S. launch of Novo's new insulin faces long delay
By Mette Fraende and Shida Chayesteh COPENHAGEN (Reuters) - Denmark's Novo Nordisk could see the U.S. launch of its biggest drug hope, a new long-acting insulin, delayed until 2018 while it conducts more tests to satisfy regulators, it said on Wednesday. The world's biggest insulin producer was dealt a major blow in February when the U.S. Food and Drug Administration (FDA) refused to approve the drug, called Tresiba, and instead asked for extra tests to assess potential heart risks. ...
Source: news.yahoo.com